KODライブシグナル | Getagraph.comで利益を最大化

買う 107876 min ago

@ $4.87

発行日: 15 2月 2024 @ 03:51

リターン: -30.29%

前回のシグナル: 2月 14 - 23:33

前回のシグナル: 売る

リターン: -1.22 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:47):

Stats
本日の出来高	138 519
平均出来高	854 622
時価総額	178.32M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-1.090 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.680
ATR14	$0.00600 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-30	Baker Bros. Advisors Lp	Buy	40 000	Non-Qualified Stock Options (right to buy)
2023-06-30	Yang Taiyin	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Profusek Robert	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Levy Richard S	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Dahiyat Bassil I	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
96.07
Last 99 transactions
Buy: 3 824 931 \| Sell: 1 385 823

ボリューム相関

長: 0.06 (neutral)

短: 0.18 (neutral)

Signal:(48.3) Neutral

Kodiak Sciences Inc 相関

10 最も正の相関
SONN	0.914
VERU	0.908
VNET	0.908
INFI	0.906
DZSI	0.903
LIVN	0.902
TCX	0.902
RYTM	0.901
PCVX	0.899
FNWB	0.897

10 最も負の相関
TYHT	-0.933
AAON	-0.913
GSHD	-0.912
PLPC	-0.905
ZGNX	-0.903
CNCE	-0.901
LNTH	-0.9
CPTA	-0.897
LMNR	-0.895
ADMS	-0.893

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kodiak Sciences Inc 相関 - 通貨/商品

0.41
( neutral )

-0.16
( neutral )

0.00
( neutral )

0.08
( neutral )

-0.62
( weak negative )

-0.06
( neutral )

Kodiak Sciences Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-25.95M (0.00 %)
EPS:	$-4.97

FY	2023
収益:	$0
総利益:	$-25.95M (0.00 %)
EPS:	$-4.97

FY	2022
収益:	$0
総利益:	$-11.00M (0.00 %)
EPS:	$6 502.21

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5.16

Financial Reports:

No articles found.

Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.